ReviewWorld journal of gastrointestinal oncology2015
Targeted therapy for advanced gastric cancer: A review of current status and future prospects.
Review in World journal of gastrointestinal oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05299476 (A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tislelizumab in First-line Treatment of PDL1 CPS < 5 Locally Advanced or Metastati Gastroesophageal Adenocarcinoma), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tislelizumab in First-line Treatment of PDL1 CPS < 5 Locally Advanced or Metastati Gastroesophageal Adenocarcinoma
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- LncRNA RUNX1-IT1 is downregulated in gastric cancer and suppresses the maturation of miR-20a by binding to its precursor.Histology and histopathology · 2023Article
- Article
- Protein-Targeted Degradation Agents Based on Natural Products.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL-17 via the Bax/Bcl-2 signaling pathway.Experimental and therapeutic medicine · 2021Article
- Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.BMB reports · 2020Article
- Review
- SPON2 Is Upregulated through Notch Signaling Pathway and Promotes Tumor Progression in Gastric Cancer.Cancers · 2020Article
- Comprehensive pharmacogenomic characterization of gastric cancer.Genome medicine · 2020Article
- HOXC10 overexpression promotes cell proliferation and migration in gastric cancer.Oncology reports · 2019Article
- Cationic amino acid transporter PQLC2 is a potential therapeutic target in gastric cancer.Cancer science · 2019Article
- Serum Inflammatory Cytokines Comparison in Gastric Cancer Therapy.Open medicine (Warsaw, Poland) · 2019Article
- Heat Shock Factor 1 Predicts Poor Prognosis of Gastric Cancer.Yonsei medical journal · 2018Article
- Annexin A7 expression is downregulated in late-stage gastric cancer and is negatively correlated with the differentiation grade and apoptosis rate.Oncology letters · 2018Article
- Contrast-enhanced computed tomography combined with Chitosan-FeExperimental and therapeutic medicine · 2018Article
- Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer.Biological procedures online · 2018Article
- Application of novel targeting nanoparticles contrast agent combined with contrast-enhanced computed tomography during screening for early-phase gastric carcinoma.Experimental and therapeutic medicine · 2018Article
- Perspective on the dynamics of cancer.Theoretical biology & medical modelling · 2017Review
- Article
- Ablation of human telomerase reverse transcriptase (hTERT) induces cellular senescence in gastric cancer through a galectin-3 dependent mechanism.Oncotarget · 2016Article
- The correlation and clinical implication of VEGF-C expression in microvascular density and lymph node metastasis of gastric carcinoma.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the West in particular, the vast majority of gastric cancer (GC) patients present with advanced-stage disease. Although combination chemotherapy is still the most important component of treatment for these patients, it confers a modest survival advantage. Recently, increased knowledge of the key molecular signaling pathways involved in gastric carcinogenesis has led to the discovery of specific molecular-targeted therapeutic agents. Some of these agents such as trastuzumab and ramucirumab have changed the treatment paradigm for this disease. In this paper, we will summarize the current clinical status of targeted drug therapy in the management of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.